January 27, 2022

Regeneron’s Antibody Drug Cuts Risk of Death in Some Covid-19 Patients

An antibody treatment developed by

Regeneron Pharmaceuticals Inc.

REGN -0.24%

has been shown to significantly cut the risk of death among certain hospitalized Covid-19 patients, raising hopes for a valuable new tool for tackling severe cases.

A large U.K. trial involving nearly 10,000 patients showed that administering REGEN-COV on top of usual care reduced the risk of dying by a fifth among hospitalized coronavirus patients who hadn’t produced antibodies to the virus. The drug had no effect among patients who had already produced antibodies.

The results released Wednesday by the U.K. researchers are a boost for a drug class that until now had only been shown to work against milder forms of the disease. Antibody therapies for Covid-19 target the spike protein on the surface of the virus with the aim of preventing it from entering cells. Earlier trials of other antibody therapies in hospitalized patients were stopped because the treatments appeared to be ineffective in these severe cases.

“This is in some ways a first,” said Martin Landray, professor of medicine and epidemiology at the University of Oxford and one of the study’s leaders. “These patients are among the sickest patients, and we have a treatment we didn’t have before.” The study is part of the U.K’s wider RECOVERY trial, which tests various drugs against Covid-19.

In the trial, REGEN-COV was used on top of dexamethasone, a steroid treatment which was shown last year to reduce the risk of dying by 17% in all hospitalized patients. “Now you’re layering the effect of steroids,” said

George Yancopoulos,

Regeneron’s president and chief scientific officer. “That’s what makes it exciting.”

Of the 9,785 participants involved in the REGEN-COV study, around a third didn’t have antibodies in their blood when they entered the trial. Some people’s immune systems don’t produce antibodies or are slow to do so for a variety of reasons, including underlying health conditions or as a result of treatments like chemotherapy, according to the investigators. These were the patients who benefited from treatment with REGEN-COV, a cocktail of two antibodies that each targets different parts of the spike protein.

Several drugmakers are developing these types of drugs, with mixed success. Some have been granted emergency-use authorization from the U.S. Food and Drug Administration for mild to moderate disease. But there have also been setbacks. On Tuesday,

AstraZeneca

PLC said its antibody therapy failed to prevent symptomatic Covid-19 in people recently exposed to the virus.

Regeneron said it would seek emergency-use authorization from the FDA for REGEN-COV among hospitalized patients. The drug has been available to treat recently diagnosed Covid-19 since November, and Regeneron has so far struck deals with the U.S. government to supply more than 1.5 million doses. In clinical trials, the drug reduced the risk of hospitalization or death by 70% in people with mild to moderate symptoms.

STAY INFORMED

Get a coronavirus briefing six days a week, and a weekly Health newsletter once the crisis abates: Sign up here.

Write to Denise Roland at Denise.Roland@wsj.com

Copyright ©2020 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Related Posts

Exxon Disavows Remarks After Video Shows Lobbyists Dismissing Company’s Climate Stance

July 1, 2021

July 1, 2021

Exxon Mobil Corp. Chief Executive Darren Woods apologized and disavowed statements made by two of the company’s top Washington lobbyists...

New York Attorney General Probe of Trump Organization Now a Criminal Investigation

May 19, 2021

May 19, 2021

New York state Attorney General Letitia James at a news conference in August last year. Photo: Kathy Willens/Associated Press Updated...

Far From Texas, Huge Gas Bills Stoke Anger After February Freeze

June 27, 2021

June 27, 2021

An angry backlash is building across the middle of the U.S. as states step in to help their constituents pay...

Real-Estate Sales Are Booming. The Rental Market Is Following Suit.

June 2, 2021

June 2, 2021

The pandemic flight patterns that saw an influx of newcomers to cities like Tampa, Fla., Austin and Detroit has transformed...

Amazon’s Planned Purchase of MGM to Be Reviewed by FTC

June 22, 2021

June 22, 2021

WASHINGTON—The Federal Trade Commission will be the agency to review Amazon. AMZN 1.41% com Inc.’s proposed acquisition of Hollywood studio...

Neiman Marcus Rides a Rebound in Luxury Shoppers

June 15, 2021

June 15, 2021

Luxury shoppers are splurging again. Neiman Marcus Group Inc.’s sales have rebounded from last year when Covid-19 closed its stores...

This Summer, Jobs Come With a Hefty Signing Bonus

July 1, 2021

July 1, 2021

Signing bonuses are usually reserved for professional athletes and a privileged few white-collar professionals. Not this summer. As U.S. employers’...

GameStop’s Chief Operating Officer Departs

October 29, 2021

October 29, 2021

GameStop Corp.’s chief operating officer, Jenna Owens, has left the company, less than a year after joining. GameStop didn’t give...

Chinese Surveillance-Gear Maker Hikvision Has Ties to Country’s Military, Report Says

May 25, 2021

May 25, 2021

HONG KONG—The world’s largest maker of surveillance equipment has long-established links to China’s military, including conducting a study with Chinese...

Biden Administration Says Child-Care Assistance Will Help Economy Grow

June 9, 2021

June 9, 2021

WASHINGTON—The Biden administration says its plan to expand access to preschool and affordable child care will help bolster long-term economic...

Apple’s Big Show May Not Be Enough

June 4, 2021

June 4, 2021

As Apple Inc. AAPL 1.81% looks to rally its base, the fate of the company’s lucrative ecosystem has never been...

Richard Branson Plans Virgin Galactic Space Trip Before Jeff Bezos

July 2, 2021

July 2, 2021

Richard Branson plans to beat Jeff Bezos to space. Virgin Galactic Holdings Inc. on Thursday said Mr. Branson plans to...

iPhone? AirPods? MacBook? You Live in Apple’s World. Here’s What You Are Missing.

June 4, 2021

June 4, 2021

Long ago, a gardener planted an iPhone.“It’s not good for a gadget to be alone,” he said.So he grew crops...

The Pizza Business Is Divided on Delivery

May 30, 2021

May 30, 2021

The industry that pioneered delivery food is divided on whether to make its pies available through apps like DoorDash DASH...

House Committee Takes on Pricing, Patents for Top-Selling Drug Humira

May 18, 2021

May 18, 2021

AbbVie Inc.’s ABBV 0.35% pricing practices for some of its top-selling medicines faced fresh scrutiny from federal lawmakers Tuesday, the...